Skip to main content

Table 3 The estimated ratio of the geometric mean number of days to recrudescence for each risk factor derived from linear regression analyses of 428 Plasmodium falciparum episodes among 354 pregnant women

From: Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort

  

Univariablea

Multivariablea

Risk factor

Categories

Nb

Ratio of geometric means (95 % CI) [P-value]

Nb

Ratio of geometric means (95 % CI) [P-value]

Parity

Primiparous

93

0.99 (0.86, 1.14) [0.890]

79

1.03 (0.89, 1.19) [0.698]

Multiparous

256

1c

212

1

Anti-malarial therapy

Artemisinin based

49

1.28 (1.09, 1.51) [0.003]

38

1.24 (1.07, 1.43) [0.003]

Non-artemisinin based

300

1

253

1

Symptoms

Symptomatic

232

0.89 (0.77, 1.03) [0.120]

211

0.94 (0.80, 1.11) [0.459]

Asymptomatic

88

1

80

1

Therapy supervision

Unsupervised

86

0.83 (0.73, 0.94) [0.004]

81

0.83 (0.73, 0.95) [0.006]

Supervised

253

1

210

1

Intercalated P. vivax

Yes

28

2.19 (1.77, 2.72) [<0.001]

25

2.19 (1.76, 2.73) [<0.001]

No

321

1

266

1

EGA (weeks)

349

349

1.00 (0.99, 1.00) [0.217]

291

1.00 (0.99, 1.00) [0.210]

Parasitaemia (m/L)d

349

349

0.98 (0.97, 1.00) [0.079]

291

0.98 (0.96, 0.99) [0.014]

Haematocrit (%)

327

327

1.00 (0.99, 1.01) [0.618]

291

1.00 (0.99, 1.01) [0.654]

  1. Combo, combination; Mono, monotherapy
  2. aOutcome is time to recrudescent infection and estimates are adjusted for age, weight and study period. Univariable, linear model included a single risk factor, age, weight and study period; Multivariable, linear model included all risk factors, age, weight and study period
  3. bThe total number of episodes (N) included in each analysis may differ from 428 due to missing risk factor data
  4. cIndicates reference group
  5. dParasitaemia was log2 transformed. Estimate interpreted as a 0.98-fold decrease in geometric mean time to recrudescent Pf infection(s) for a doubling in parasitaemia